The role of selected chemokines and their receptors in the pathogenesis and destabilisation of atheromatous plaques in the carotid arteries

被引:1
作者
Konarska-Krol, Maria [1 ]
Kacperska, Magdalena Justyna [2 ]
Walenczak, Jakub [2 ]
Tomasik, Bartlomiej [2 ]
Szpakowski, Piotr [3 ]
机构
[1] Nicolaus Copernicus Hosp Lodz, Stroke Ctr, Dept Neurol, Pabianicka 62, PL-93513 Lodz, Poland
[2] Med Univ Lodz, Lodz, Poland
[3] Med Univ Lodz, Dept Neurol & Stroke, Lodz, Poland
来源
AKTUALNOSCI NEUROLOGICZNE | 2015年 / 15卷 / 01期
关键词
chemokines; chemokine receptors; atheromatous plaque; mediators of inflammation;
D O I
10.15557/AN.2015.0007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Chemokines are cytokines that act selectively on cells and are capable of inducing selective migration of cells in vitro and in vivo. The term was first coined at the 3rd International Symposium on Chemotactic Cytokines in 1992. The name "chemokine" is a contraction of "chemotactic cytokine," meaning that these molecules combine features of both cytokines and chemotactic factors. They are a family of low-molecular-mass proteins acting on specific membrane receptors. A cell's overall sensitivity to chemotaxis depends on the expression profile of chemokine receptors. Atherosclerosis is essentially an excessive inflammatory and proliferative response to the damage of arterial walls. It takes place within the wall and leads to the formation of unstable atherosclerotic plaques. Many chemokines have been studied in terms of their role in the pathogenesis of an atheromatous plaque in the carotid arteries, both in animal models and with the use of human tissue. It seems that molecules that are the most involved in the formation of atheromas in the carotid arteries include: CCL2, CCL3, CCL4 and CCL5. However, reports are sometimes contradictory, and more research is needed. Finding a marker that could help predict the destabilisation of an atheromatous plaque would be a valuable addition to the standard diagnostic panel of tests used in both the diagnosis and monitoring of vascular pathologies.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 32 条
[1]   Chemokines in pathology and medicine [J].
Baggiolini, M .
JOURNAL OF INTERNAL MEDICINE, 2001, 250 (02) :91-104
[2]   Human chemokines: An update [J].
Baggiolini, M ;
Dewald, B ;
Moser, B .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :675-705
[3]   RANTES gene polymorphisms redict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients [J].
Böger, CA ;
Fischereder, M ;
Deinzer, M ;
Aslanidis, C ;
Schmitz, G ;
Stubanus, M ;
Banas, B ;
Krüger, B ;
Riegger, GAJ ;
Krämer, BK .
ATHEROSCLEROSIS, 2005, 183 (01) :121-129
[4]   Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J].
Boring, L ;
Gosling, J ;
Cleary, M ;
Charo, IF .
NATURE, 1998, 394 (6696) :894-897
[5]   Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice [J].
Braunersreuther, Vincent ;
Zernecke, Alma ;
Arnaud, Claire ;
Liehn, Elisa A. ;
Steffens, Sabine ;
Shagdarsuren, Erdenechimeg ;
Bidzhekov, Kiril ;
Burger, Fabienne ;
Pelli, Graziano ;
Luckow, Bruno ;
Mach, Francois ;
Weber, Christian .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (02) :373-379
[6]   Role of chemokines in the development of secondary and tertiary lymphoid tissues [J].
Cupedo, T ;
Mebius, RE .
SEMINARS IN IMMUNOLOGY, 2003, 15 (05) :243-248
[7]   Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? [J].
de Boer, OJ ;
van der Wal, AC ;
Teeling, P ;
Becker, AE .
CARDIOVASCULAR RESEARCH, 1999, 41 (02) :443-449
[8]   Structure junction, and inhibition of chemokines [J].
Fernandez, EJ ;
Lolis, E .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :469-499
[9]   The unstable plaque [J].
Hennerici, MG .
CEREBROVASCULAR DISEASES, 2004, 17 :17-22
[10]   Monocyte chemoattractant protein-1 and coronary artery disease [J].
Ikeda, U ;
Matsui, K ;
Murakami, Y ;
Shimada, K .
CLINICAL CARDIOLOGY, 2002, 25 (04) :143-147